Last update 03 Jan 2026

CCR2-targeting siRNA therapy (Alnylam/MGH/MIT)

Overview

Basic Info

Drug Type
siRNA
Synonyms-
Target
CCR2
Action
antagonists
Mechanism
CCR2 antagonists(C-C chemokine receptor type 2 antagonists)
Therapeutic Areas
NeoplasmsImmune System DiseasesCardiovascular Diseases+ [1]
Active Indication-
Inactive Indication
Cardiovascular DiseasesGraft RejectionInflammation+ [1]
Originator Organization
The Massachusetts General HospitalThe Massachusetts General HospitalAlnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc.Massachusetts Institute of TechnologyMassachusetts Institute of Technology
Active Organization-
Inactive Organization
The Massachusetts General HospitalThe Massachusetts General HospitalAlnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc.Massachusetts Institute of TechnologyMassachusetts Institute of Technology
License Organization-
Drug Highest PhasePendingPreclinical
First Approval Date-
Regulation-

Structure/Sequence

Boost your research with our RNA technology data.
login
or
view full example data
Boost your research with our RNA technology data.

Related

100 Clinical Results associated with CCR2-targeting siRNA therapy (Alnylam/MGH/MIT)
Login to view more data
100 Translational Medicine associated with CCR2-targeting siRNA therapy (Alnylam/MGH/MIT)
Login to view more data
100 Patents (Medical) associated with CCR2-targeting siRNA therapy (Alnylam/MGH/MIT)
Login to view more data
100 Deals associated with CCR2-targeting siRNA therapy (Alnylam/MGH/MIT)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cardiovascular DiseasesPreclinical
United States
Massachusetts Institute of TechnologyMassachusetts Institute of Technology
11 Oct 2011
Cardiovascular DiseasesPreclinical
United States
Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc.
11 Oct 2011
Cardiovascular DiseasesPreclinical
United States
The Massachusetts General HospitalThe Massachusetts General Hospital
11 Oct 2011
Graft RejectionPreclinical
United States
Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc.
11 Oct 2011
Graft RejectionPreclinical
United States
Massachusetts Institute of TechnologyMassachusetts Institute of Technology
11 Oct 2011
Graft RejectionPreclinical
United States
The Massachusetts General HospitalThe Massachusetts General Hospital
11 Oct 2011
InflammationPreclinical
United States
Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc.
11 Oct 2011
InflammationPreclinical
United States
Massachusetts Institute of TechnologyMassachusetts Institute of Technology
11 Oct 2011
InflammationPreclinical
United States
The Massachusetts General HospitalThe Massachusetts General Hospital
11 Oct 2011
NeoplasmsPreclinical
United States
The Massachusetts General HospitalThe Massachusetts General Hospital
11 Oct 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free